Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study

Publication date: Available online 6 May 2021Source: The Lancet Respiratory MedicineAuthor(s): Jordana E Hoppe, Mark Chilvers, Felix Ratjen, John J McNamara, Caroline A Owen, Simon Tian, Rachel Zahigian, Alexandra G Cornell, Susanna A McColley
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research